This systematic review synthesizes evidence from seven high-quality studies evaluating the cardiovascular and renal benefits of SGLT2 inhibitors and GLP-1 RAs in patients with type 2 diabetes. Here, GLP1R is linked to type 2 diabetes mellitus.